Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects

Inclusion Criteria:

• • Chinese subjects at least 18 years of age.
• • Chronic Kidney Disease (CKD) stage 3 and 4.
• • Mean of 2 measurement of serum potassium higher than 5.0 and lower than 6.5 mEq/Lat baseline.
• • Subjects on any stable dose of at least 1 RAASi medication for at least 28 daysbefore Day 0/baseline.
• • If on antihypertensive medication, have a stable dose for 28 days before Day 0/baseline.
• • Women of childbearing potential must agree to continue using contraceptionthroughout the study and for 4 weeks after study completion.

Exclusion Criteria:

• • Any level of hyperkalemia at Day 0/baseline that, in the opinion of theInvestigator, requires emergency intervention.
• • Type 1 diabetes or Type 2 diabetes mellitus with glycated haemoglobin (Hb A1c)higher than 10.0% at screening/Part A baseline.
• • History of acute renal insufficiency in the past 3 months prior to the beginningof the study.
• • Diseases affecting the hearth muscle and heart's ability to pump blood around thebody
• • Major surgery including thoracic and cardiac within 3 months prior to thebeginning of the study or anticipated need during study participation.
• • Heart or kidney transplant recipient or anticipated need for transplant duringstudy participation
• • Diagnosis or treatment of a malignancy in the past 2 years before Day 0/baseline.
• • Use of potassium supplements, bicarbonate or baking soda in the last 7 days priorto Day 0/baseline.
• • Pregnant women or breastfeeding.